KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Change in Accured Expenses: 2010-2025

Historic Change in Accured Expenses for Nektar Therapeutics (NKTR) over the last 16 years, with Sep 2025 value amounting to -$7.0 million.

  • Nektar Therapeutics' Change in Accured Expenses fell 206.92% to -$7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.6 million, marking a year-over-year decrease of 227.42%. This contributed to the annual value of $10.7 million for FY2024, which is 162.17% up from last year.
  • Nektar Therapeutics' Change in Accured Expenses amounted to -$7.0 million in Q3 2025, which was down 356.95% from $2.7 million recorded in Q2 2025.
  • In the past 5 years, Nektar Therapeutics' Change in Accured Expenses registered a high of $14.2 million during Q1 2022, and its lowest value of -$41.3 million during Q4 2021.
  • For the 3-year period, Nektar Therapeutics' Change in Accured Expenses averaged around -$872,091, with its median value being $1.2 million (2025).
  • In the last 5 years, Nektar Therapeutics' Change in Accured Expenses tumbled by 770.70% in 2023 and then spiked by 1,489.56% in 2024.
  • Nektar Therapeutics' Change in Accured Expenses (Quarterly) stood at -$41.3 million in 2021, then skyrocketed by 47.79% to -$21.5 million in 2022, then surged by 54.77% to -$9.7 million in 2023, then surged by 32.45% to -$6.6 million in 2024, then plummeted by 206.92% to -$7.0 million in 2025.
  • Its Change in Accured Expenses stands at -$7.0 million for Q3 2025, versus $2.7 million for Q2 2025 and $1.2 million for Q1 2025.